FORT WORTH, Texas, July 15 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) is pleasedto announce another milestone in its planned growth strategy. Its subsidiary, Wound Care Innovations, L.L.C., signed a distribution agreement with Healing Innovation, Ltd. of Belize to facilitate the sale of CellerateRx®
"The new sales team that we put in place at Wound Care Innovations in the second quarter of 2010 has signed this critical new distributor agreement within the first ninety days on the job. We are all very excited about what this deal means for our company's expansion into international markets both today and in the future," stated Deborah Jenkins Hutchinson, President of Wound Management Technologies, Inc.
Cathy Bradshaw, President of Wound Care Innovations was quoted as saying, "We are proud of the expanding international sales of our advanced wound care collagen product, CellerateRx®, into Central America. Our team looks forward to additionally selling our products in the European Union by the end of the year." Bradshaw continued, "We are also very excited to welcome KOMED, LLC as a distribution partner here in the United States who began selling our CellerateRx® product as of July 1st from Texas to the Carolinas."
To receive current news and information about Wound Management Technologies and its companies subscribe to join the WNDM email distribution list on the home page or investor page of www.wmgtech.com
For Wound Management Technologies Shareholder Information please call 817-820-7077 or go to http://www.wmgtech.com
About Wound Care Innovations, LLC
Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on CellerateRx, please visit the WCI web site at http://www.celleraterx.com/ .
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, CellerateRx®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years WMT has focused on developing evidenced-based studies on CellerateRX and gaining physician awareness by participation in key industry conferences. Now WMT is focused on expanding sales through partnerships and contracted independent representatives. WMT has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com, http://www.celleraterx.com , and http://www.secureehealth.com .
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
SOURCE Wound Management Technologies, Inc.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All